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The clinical description of a dysmorphic syndrome 
by Smith, Lemli and Opitz in 1964[1] was linked with 
abnormal sterol biosynthesis 30 years later. [2] A sys­
tematic review[3] of the effects of abnormal choles terol 
biosynthesis indicated that the plasma accumulates 
7­dehydrocholesterol and its precursor, and is often associated with 
hypocholesterolaemia. Nevertheless, the cholesterol concentration 
may be in the normal range and should not be a deterrent for 
further investigation when the clinical features are suggestive of 
this syndrome. Faecal and biliary sterols are abnormal, and bile 
acid metabolism is also affected. Porter[4,5] reviewed cholesterol 
biosynthetic errors. Cholesterol precursors that accumulate in Smith­
Lemli­Opitz syndrome (SLOS), lathosterolosis and desmosterolosis 
disrupt intrauterine development at a critical period of facial and 
brain development, when cholesterol binds covalently to sonic 
hedgehog protein involved in signalling to responding cells.[6] Engel­
king[7] investigated the pathogenesis in a mouse model, and demon­
strated that the precursors were operative in bringing about the 
abnormalities rather than the lack of cholesterol, as suppression of 
the production of precursors by lovastatin ameliorated the condition. 
A clinical review[8] indicated the prevalence of SLOS to be between 
1 in 20 000 ­ 70 000 births in individuals of European descent, with 
a gene frequency of ~1% for a mutation in 7­dehydrocholesterol 
reductase (7DHCR). The clinical spectrum of manifestations is broad, 
but can be summarised as craniofacial abnormalities including cleft 
palate and microcephaly, postaxial polydactyly and syndactyly of the 
toes, cardiac defects, pyloric stenosis, aganglionosis of the colon and 
ambiguous genitalia. Failure to thrive, hypotonia and developmental 
delay as well as self­injurious behaviour and autism are reported. 
Photosensitivity may be marked. The manifestations depend on 
the severity of the disruption of enzyme activity, and compensatory 
mechanisms may vary as well. The spectrum has been subdivided 
into the severe extreme (type 2) and the less severe (type 1); the 
latter may not be clinically recognised until developmental delay or 
behavioural problems are noticed. The fetal manifestations have been 
documented.[9] The diagnosis is best made by gas chromatography 
and mass spectrometry, but ultraviolet spectrophotometry can detect 
7­dehydrocholesterol in extracts from plasma;[10] however, other 
abnormal precursor sterols could be overlooked by this method. 
Dried blood spot analysis may not be ideal, as 7­dehydrocholesterol 
is prone to oxidation.[11] Amniotic fluid can be used to confirm the 
diagnosis antenatally.[12]  
The genetic causes of SLOS in Europe have been summarised[13] 
and compared with those in the USA. There were some differences in 
distribution in the European countries, but by far the most common 
mutation (35%) was at the intron­exon junction of exon 8, with 
p.trp151X (10%), p.thr95met (8%) and p.val326leu (7%). The first 
two mutations may have appeared ~3 000 years ago in north­west 
and north­east Europe. It is not clear whether the heterozygous state 
confers an advantage, but 7­dehydrocholesterol is the precursor to 
forming vitamin D in the skin. 
Information about SLOS is limited in South Africa (SA). A 
diagnosis on clinical grounds has been reported.[14,15] In this article, 
we report experience with referred cases and wish to make medical 
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Background. The Smith­Lemli­Opitz syndrome (SLOS), due to defective function of 7­dehydrocholesterol reductase, is an autosomal 
recessive disorder that is more common than other defects in cholesterol biosynthesis. The dysmorphology can be suggestive, but bio­
chemical and genetic investigations are required for confirmation of this diagnosis to assist with the management of the patient and 
planning for future children in affected families. 
Objective. To perform biochemical and genetic work­ups in four South African families of European ancestry with suspected SLOS in a 
range of presentations, from early fatality, congenital malformations, feeding problems and developmental delay.
Methods. Plasma was analysed by ultraviolet spectrophotometry. The genetic cause was investigated by polymerase chain reaction, followed 
by high­resolution melting and sequencing of amplicons displaying abnormal patterns. 
Results. Spectrophotometry confirmed the diagnosis in three families. Genetic confirmation was made in these patients, and carrier status 
confirmed in the parents of the fatal case. All the patients were of European ancestry, and the mutations reflected those in European studies. 
Conclusion. This rare disorder should be considered in antenatal assessment when increased nuchal lucency is detected on sonography, or 
in newborns with syndactyly, hypotonia and feeding problems. Less severe forms could present with developmental delay and behavioural 
problems. Confirmation of the diagnosis may assist in decisions about nutritional management as well as future pregnancies in the affected 
family and primary relatives.
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practitioners aware of this condition in order 
to improve diagnosis, antenatal diagnosis 
and genetic counselling, as well as to ensure 
optimal management. 
Methods
Blood samples (anticoagulated with ethylene 
diamine tetra­acetate) were accepted 
from referring medical practitioners who 
suspected SLOS on clinical grounds, 
including samples from the parents, with 
fasting lipid profiles when possible. Consent 
for genetic diagnosis was obtained by the 
medical practitioners. A brief description is 
given for each family in order of referral. The 
information is summarised in Table 1 along 
with the results of genetic investigation. 
Family 1 
The first­born boy to unrelated parents had 
abnormal nuchal translucency by sono­
graphic examination at 12 weeks of gestation. 
Later, short femora and a ventricular septal 
defect were identified. At birth by caesarean 
section in 2008, microcephaly, hypospadias 
and syndactyly (Fig. 1) were noted along 
with hypotonia and poor sucking reflexes. 
Neurological development was impaired 
and feeding difficulties were encountered. 
Nasogastric feeding was under taken and later 
a gastrostomy was performed for feeding. 
The plasma cholesterol concentration was 
1.1 ­ 1.5 mmol/L. Cholesterol intake was 
increased, and plasma cholesterol rose to 
3.5 mmol/L. The impression was that such 
feeding improved wellbeing and behaviour. 
The raised plasma 7­dehydrocholesterol 
(750 μmol/L) was confirmed by ultraviolet 
spectrophotometry. Transaminase elevation 
was noted and considered to be part of the 
inherited disorder. At the age of 4 years, his 
mass is 22 kg and his height is 0.98 m. He 
can indicate his wishes but cannot speak. He 
lives at home and attends a schooling facility 
during the day. 
Family 2 
The first­born girl of unrelated healthy 
parents had an unremarkable antenatal 
course, but at caesarean section in 2011 was 
noted to be hypotonic, microcephalic, had 
bifrontal narrowing, small palpebral fissures, 
anteverted nares, syndactyly on the feet 
and mild deformities of the hand. Feeding 
difficulties included poor swallowing, 
reflux and vomiting. A gastrostomy was 
performed to assist with feeding at 4 months 
and a Nissen fundoplication was performed 
to deal with reflux. The biochemical 
diagnosis of SLOS was made at the age of 
6 months, with a 7­dehydrocholesterol 
concentration of 836 μmol/L. With dietetic 
help, choles terol supplementation was 
undertaken with a synthetic nutritional 
formula; staff involved in her treatment 
were of the opinion that she improved. The 
plasma cholesterol concentrations ranged 
from 3.3 to 4.1 mmol/L on cholesterol 
supplementation. On combination treatment 
with simvastatin (0.3 mg/kg/day), plasma 
7­dehydrocholesterol was 0.125 μmol/L. 
Head banging, finger biting and pulling of 
hair started at 14 months. Investigations 
for ataxia revealed abnormalities of the 
cerebellar vermis on nuclear magnetic 
resonance imaging. At the age of 2 years, 
her developmental assessment placed her at 
1 year and she had begun developing autistic 
behaviour. 
Family 3 
The first daughter was born with defects 
and died without a diagnosis within hours, 
in 1987. The second daughter, born in 
1989, had multiple abnormalities including 
microcephaly, syndactyly and no nasal 
bridge. She also had a cleft palate. Tube 
feeding was instituted and projectile vomiting 
was noted. The cleft palate was repaired after 
a year, but feeding remained problematic. 
She required positioning so that liquid diets 
could drain into the stomach. Repeated ear 
infections resulted in admissions to hospital. 
Self­injurious behaviour was noted early on, 
necessitating the use of a protective helmet. 
She did eventually lose sight in both eyes 
owing to injury. At the age of 24 years, she 
has a height of 1.13 m and a mass of 22 kg. 
She cannot speak, is unable to sit on her 
own, sleeps little and is incontinent. When 
sedation was required, diazepam and most 
other commonly used agents failed, but 
hydroxyzine was suitable. The third child 
does not have SLOS. 
 
Family 4 
The first boy of unrelated healthy parents was 
born with a mass of 2.38 kg and low Apgar 
scores. There were multiple defects and he 
died on the second day. The antenatal course, 
including sonography, was unremarkable. At 
birth, the following features were recorded: 
webbed neck, rockerbottom feet, polydactyly 
of the hands and feet, and cardiac murmur. 
The clinical diagnosis of SLOS was suggest­
ed. The next pregnancy terminated spon­
taneously, but thereafter a normal female 
child was born. The diagnosis was pursued 
in order to counsel the primary relatives, as 
two brothers had married two sisters. 
Biochemical diagnosis
Plasma was separated and sterols were 
extracted into hexane.[10] Absorbances were 
Table 1. Clinical, laboratory and genetic findings in four families with Smith-Lemli-
Opitz syndrome
Family 1 Family 2 Family 3 Family 4
Index birth 2008 2011 1989 2011
Status Alive Alive Alive Deceased
Gender Male Female Female Male 
Ethnicity* Afrikaans English English Afrikaans
Syndactyly† Yes Yes Yes Yes
Microcephaly Yes Yes Yes Yes
Hypotonia Yes Yes Yes Yes
Cleft palate No No Yes No
Developmental delay Yes Yes Yes n/a
Injurious behaviour Yes Yes Yes n/a
Feeding difficulty Yes Yes Yes n/a
Abs 282/234 (nm) 3.08 3.12 1.95 n/a
Mutation maternal G410S T289I T93M W151X
Mutation paternal G410S W151X IVS8­1G>C V281M
Abs = absorption.
*All patients were classified as white, with language group indicating present self­identification. 
† Syndactyly is of second and third toes. The rays appear divergent rather than the common abnormality, which 
appears parallel. 
Fig. 1. Syndactyly of second and third digits of the 
foot in the patient from family 1.
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recorded at 234 nm and 282 nm, and the 
ratio was calculated. The molar extinction 
coefficient was deter mined with commercially 
available 7­dehydro cholesterol. The presence 
of 7­dehydro cholesterol was confirmed by 
argentation thin­layer chromatography.
Genetic diagnosis
Genomic DNA was extracted using the 
QIAamp DNA Mini Kit from Qiagen (USA) 
and screened for mutations in the DHCR7 
gene using quantitative real­time polymerase 
chain reaction (PCR) high­resolution 
melting (HRM) (RT­qPCR­HRM). 
Primer pairs were designed to amplify 
the coding exons 3 ­ 9 of the DHCR7 gene, 
with amplicon lengths ranging from 160 to 
370 base pairs (Table 2). Primer melting 
temperatures were adjusted for the LCGreen 
family of double­stranded DNA binding 
dyes. Each exon was analysed in a single 
PCR product, except exon 9, which was split 
into two amplicons. Samples were amplified 
on the LightScanner32 (Idaho Technology 
Inc, USA), an HRM­enabled, real­time 
PCR machine, and screened for sequence 
variations by curve analysis in a single run. 
PCR was performed in a 10 µL reaction 
volume containing 50 ng of genomic DNA, 
0.5 µM of each primer, 1× (undiluted) 
LightScanner Master Mix and PCR­grade 
water to adjust to the total volume of 10 µL. 
If necessary, 0.5% dimethyl sulphoxide 
(DMSO) was added to the reaction. The 
reaction conditions included an activation 
step at 95oC for 2 minutes, followed by 
40 cycles of 95oC for 10 seconds, variable 
melting temperatures for 20 seconds, and 
72oC for 20 seconds. Before the HRM step, 
products were denatured at 95oC for 5 seconds 
and renatured at 40oC for 30 seconds. HRM 
was carried out over the range of 60oC to 
95oC, with a ramp rate of 0.3oC/s. 
Results   
The spectrophotometric analysis proved 
effective for the diagnosis of SLOS, as the 
ratio of absorbances at 234 nm and 282 nm 
was unequivocally raised in the patients 
when compared with a large number of 
control plasma samples. The patients from 
families 1, 2 and 3 had ratios of 3.08, 3.12 and 
1.95, respectively (normal ratio <0.30). 
The mutations identified were all 
previously reported to be pathogenic, and 
only one patient was a true homozygote 
for a pathogenic mutation. The mutations 
and their association with the parents are 
indicated in Table 1. The mutations were: 
exon 4 (threonine substituted by methionine 
at amino acid 93, T93M), exon 6 (tryptophan 
codon results in a stop of translation, 
W151X), exon 8 (threonine substituted by 
isoleucine at amino acid 289, T289I) and at 
the junction of the 8th intron and 9th exon, 
IVS8­1). 
Discussion
Healthcare in SA is constrained by 
limited resources, and the focus is on 
primary healthcare, including antenatal 
care, childbirth and health of the infant. 
The emphasis on the most common 
disorders is appropriate, but patients 
with uncommon or severe disorders, 
especially those that develop complications 
competing for facilities and resources, 
should at least have a diagnosis for making 
decisions about management. Not only 
is there a need for assessment of these 
patients by gynaecologists, obstetricians 
and paediatricians, but also by clinical 
geneticists. Special biochemical and 
genetic investigations that are essential for 
a diagnosis are limited in SA. We describe 
four cases in whom the most common 
severe cholesterol biosynthetic error was 
fully characterised in families of European 
ancestry. Not unexpectedly, the mutations 
correspond with the most frequently 
reported mutations in Europe, and the 
clinical manifestations are similar.
The prevalence of SLOS as well as the 
carrier frequency of this recessive disorder 
is not well studied in populations other 
than those of European descent. The clinical 
features of SLOS are somewhat nonspecific 
and can vary. The dysmorphology may be 
less striking with age. The features that 
could indicate SLOS during pregnancy are 
increased nuchal lucency and the presence 
of various malformations. Diagnosis can 
be made on the amniotic fluid, which 
has been studied for the presence of 7­ 
and/or 8­dehydrocholesterol and its ratio 
to total cholesterol.[12,16] The expression 
of the disorder is not only related to the 
residual enzyme activity but also to certain 
modifying factors. The clinical appearance 
at birth is suggestive but not specific, as 
other disorders need to be considered 
because several clinical features are shared, 
especially two other cholesterol biosynthetic 
errors (desmosterolosis, lathosterolosis). 
A careful evaluation should differentiate 
SLOS from Williams syndrome, Wolf­
Hirschhorn syndrome, Smith­Magenis 
syndrome, Malpuech syndrome, Rett 
syndrome, craniofacial ciliopathies as well 
as disorders that can render male genitalia 
ambiguous. Feeding difficulties and failure 
to thrive may arise in the neonatal and 
infantile period. Nutritional support in this 
period may require special care for adequate 
energy and nutrient intake, and mode of 
delivery: nasogastric tube feeding may 
suffice but percutaneous gastric feeding may 
be required. Confirmation of the diagnosis 
indicates that the child will continue failing 
to thrive, and will need more aggressive 
intervention for feeding. It is uncertain 
whether a cholesterol­enriched diet 
improves development, as the brain relies on 
de novo synthesis of cholesterol. Simvastatin, 
as an inhibitor of hydroxy­methylglutaryl 
co­enzyme A reductase, will limit the 
production of both 7­dehydrocholesterol 
and cholesterol, with the former building 
up as a result of the defect in this disorder. 
If there is residual activity to synthesise 
cholesterol but a reduction of its precursor 
that may adversely affect its function(s), 
then there may be improvement. There 
has, however, been a cautionary note 
about this therapy.[18] Developmental delay, 
behavioural problems and autism may later 
lead to the identification of SLOS. Moreover, 
termination of pregnancy may be elected 
when there is an antenatal diagnosis of the 
disorder, especially in those with a severe 
phenotype. Proving the diagnosis may thus 
enhance clinical decisions on management, 
minimise hospitalisation and reduce 
expenses for unnecessary investigations, of 
which some may be very expensive. 
In Europe, the most common four 
mutations overall account for 60% of SLOS. 
These four mutations were identified in 
the first four families of European ancestry 
in SA in whom the diagnosis of SLOS was 
made. This rare disorder appears not to 
have a prominent founder effect in SA, as 
there is a range of mutations. Furthermore, 
Table 2. Primers for amplification of translated exons in DHCR7
Amplicon Forward primer 5’ - 3’ Reverse primer 5’ - 3’
Exon 3 CCAGGAGCAGTGGTGGA CTAGCTGGGAGAACAGGC
Exon 4 CCAGTGTGACTGCCTGCAT CAGGGCAGGGGCTGCTGA
Exon 5 TTTGCAGGTGCCCTCCAGGCG GGGATGAGAACGGGAGCCTGGG
Exon 6 GAAAGCGCCTTCATTTCTGAATC CCCGCTGCTAAGAACATACC
Exon 7 GCTTCATCTTGTGAGATATGCTCATCC ATCGGCGTTTCACCCTCT
Exon 8 TGATTTCCCCGAGGTCC CTCTGCCCACCTCCTCA
Exon 9a CGAGCCCACACTCCTGTC CACAGGCCAGGCAGTAG
Exon 9b CAGAGGCACCACAGCAA CCCTAGGGCGTGCCCTT
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there are three mutations in the two families of Afrikaner ancestry. 
The parents of the child in family 1 traced back their family without 
convergence until at least 1740. Systematic genetic detection of 
mutations in 7DHCR in the population at large is not warranted 
owing to the rarity of the condition, but consideration should 
be given to this disorder if antenatal development is abnormal. 
Biochemical confirmation of the diagnosis of SLOS without genetic 
substantiation will allow correct counselling about the risk of the 
condition being present in 25% of future pregnancies. Genetic 
identification will allow detection of carriers in the parents’ siblings 
and other relatives, whose offspring should be monitored more 
closely, as the frequency for mutations in 7DHCR is suspected in 
about 1% of European populations. 
The formal diagnosis of SLOS by gas chromatography and mass 
spectrometry is not available in SA. Such diagnostic investigation 
proved unaffordable in overseas laboratories, as these and other 
costs in management are supported to only a limited extent 
by medical schemes, and state hospitals and clinics and their 
laboratory services. However, the spectrophotometric test is reliable 
and affordable, and has been shown to be suitable for amniotic 
fluid extracts with confirmation on thin­layer chromatography. 
In the case of SLOS, the concurrence of syndactyly, hypotonia, 
feeding difficulties and other malformations is highly suggestive 
of the diagnosis. Ideally, the index of suspicion for severe inherited 
metabolic disorders should be raised in order that referral and 
investigation will lead to diagnosis and optimal management amid 
limited resources. Specialised centres in which clinics work in 
conjunction with specialised laboratories should be supported to 
provide for the increasing need to diagnose and manage metabolic 
disorders that are amenable to biochemical and/or genetic 
diagnosis. Once the mutations have been identified, chorionic 
villus biopsy can be undertaken to identify the disorder at the 11th 
week of pregnancy. Not only would such centres assist in reducing 
the burden of SLOS within the affected families, but they would 
also provide important information for teaching and planning of 
healthcare in SA. 
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